首页|中国肥胖症药物治疗的现状及效果分析

中国肥胖症药物治疗的现状及效果分析

扫码查看
中国超重肥胖症患者日益增加,目前的减重治疗方式包括生活方式干预、药物治疗、代谢手术等.近年来,减重药物取得显著进展且减重效果良好,不仅帮助控制体重,而且能预防肥胖症相关并发症的发生发展,是减重治疗的重要手段之一.然而目前国内获批减重适应症的药物较少,而社会对减重药物的需求却日益增大.本研究通过阐述中国肥胖症治疗的现状,总结及分析肥胖症药物治疗的启动时机、治疗目标、药物类型等,希望可以为肥胖症的药物治疗提供参考,支持和促进我国肥胖临床治疗实践的规范化发展,让更多超重肥胖症患者获益.
Current status and effect analysis of pharmacological treatment for obesity in China
The prevalence of overweight and obesity in China is rising rapidly.Current treatment for weight loss includes lifestyle interventions,pharmacotherapy,and metabolic surgery.In recent years,pharmacotherapy for weight loss has shown significant efficiency,with good weight-loss effects,which can not only control body weight but also prevent obesity-related complications.However,currently,there are relatively few approved weight-loss drugs in China,while the social demand for weight-loss drugs in society is increasing.Therefore,this study aims to provide a reference for the pharmacological treatment of obesity by elucidating the current status of obesity treatment in China,summarizing and analyzing the initiation timing,treatment goals,and types of drugs for obesity treatment.It is hoped that this will support and promote the standardized development of clinical practices for obesity in China,benefiting more overweight and obese patients.

ObesityWeight lossPharmacological therapyGlucagon-like peptide-1 receptor agonists

谭莺、雷普润、唐齐、魏炜、孙晓敏、王友发、陈燕铭

展开 >

中山大学附属第三医院内分泌与代谢病学科 广东省糖尿病防治重点实验室,广东 广州,510630

中山大学附属第三医院胃肠外科

西安交通大学全球健康研究院 公共卫生学院 国际肥胖与代谢病研究中心

中国医科大学健康科学研究院

中山大学附属第三医院临床免疫中心

展开 >

肥胖 减重 药物治疗 胰高血糖素样肽-1受体激动剂

国家自然科学基金中山大学临床医学研究5010计划

822708862023006

2024

中国预防医学杂志
中华预防医学会

中国预防医学杂志

CSTPCD
影响因子:1.004
ISSN:1009-6639
年,卷(期):2024.25(4)